Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arrowhead Pharma 177 E. Colorado Blvd Suite 700 Pasadena CA 91105 USA

www.arrowheadpharma.com Employees: 609 P: 626-304-3400 F: 626-304-3401

Description:

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Key Statistics

Overview:

Market Capitalization, $K 2,457,571
Enterprise Value, $K 2,748,061
Shares Outstanding, K 124,434
Annual Sales, $ 3,550 K
Annual Net Income, $ -599,490 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -170,540 K
EBIT, $ -601,080 K
EBITDA, $ -585,730 K
60-Month Beta 0.90
% of Insider Shareholders 4.50%
% of Institutional Shareholders 62.61%
Float, K 118,834
% Float 95.50%
Short Volume Ratio 0.31

Growth:

1-Year Return -34.93%
3-Year Return -70.21%
5-Year Return -67.92%
5-Year Revenue Growth -97.90%
5-Year Earnings Growth -824.64%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.38 on 11/26/24
Next Earnings Date 02/04/25
Earnings Per Share ttm -5.02
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -33.98%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/17/11

ARWR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -182.69%
Return-on-Assets % -64.04%
Profit Margin % -16,887.04%
Debt/Equity 2.06
Price/Sales 681.57
Price/Cash Flow N/A
Price/Book 12.65
Book Value/Share 1.54
Interest Coverage -17.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar